Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 363-375

  Däbritz, Jan ^a,b,c   Musci, Jason ^b   Foell, Dirk ^c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Calprotectin; Defensins; Granins; Irritable bowel syndrome; Lactoferrin; M2 pyruvate kinase; Polymorphonuclear elastase; S100A12

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA DEFENSIN 2; BIOLOGICAL MARKER; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; CHROMOGRANIN; DEFENSIN; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; FAECAL BIOMARKER; GELATINASE B; LACTOFERRIN; MYELOPEROXIDASE; POLYMORPHONUCLEAR ELASTASE; PROTEIN S 100; PYRUVATE KINASE ISOENZYME M 2; S100 A12 PROTEIN; SECRETOGRANIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC VALUE; ENDOSCOPY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; META ANALYSIS (TOPIC); PREDICTIVE VALUE; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ANIMAL; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; FECES; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; METABOLISM; PROGNOSIS;

ANIMALS; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84892837620     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.363     Document Type: Review

References (92)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721. e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]
2. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-5163 [PMID: 23066308 DOI: 10.3748/wjg.v18.i37.5151]
3. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012; 345: e5836 [PMID: 22951548 DOI: 10.1136/bmj.e5836]
4. Chang JY, Talley NJ. An update on irritable bowel syndrome: from diagnosis to emerging therapies. Curr Opin Gastroenterol 2011; 27: 72-78 [PMID: 21099429 DOI: 10.1097/ MOG.0b013e3283414065]
5. Agréus L, Svärdsudd K, Nyrén O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-680 [PMID: 7657095 DOI: 10.1016/0016-5085(95)90373-9]
6. Drossman DA, Morris CB, Hu Y, Toner BB, Diamant N, Leserman J, Shetzline M, Dalton C, Bangdiwala SI. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology 2005; 128: 580-589 [PMID: 15765393 DOI: 10.1053/ j.gastro.2004.12.006]
7. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 Suppl 1: S1-35 [PMID: 19521341 DOI: 10.1038/ajg.2008.122]
8. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-654 [PMID: 698649]
9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1053/ j.gastro.2005.11.061]
10. American Gastroenterology Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002; 123: 2105-2107 [PMID: 12454865 DOI: 10.1053/gast.2002.37095b]
11. Whitehead WE, Palsson OS, Feld AD, Levy RL, VON Korff M, Turner MJ, Drossman DA. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. Aliment Pharmacol Ther 2006; 24: 137-146 [PMID: 16803612 DOI: 10.1111/j.1365-2036.2006.02956.x]
12. Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004; 53: 1806-1812 [PMID: 15542519 DOI: 10.1136/gut.2003.036418]
13. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927-934 [PMID: 8633583]
14. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009; 58: 859-868 [PMID: 19136508 DOI: 10.1136/gut.2008.170019]
15. Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 1755-1762 [PMID: 12135031 DOI: 10.1111/j.1572-0241.2002.05837.x]
16. van der Sluys Veer A, Biemond I, Verspaget HW, Lamers CB. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol Suppl 1999; 230: 106-110 [PMID: 10499470 DOI: 10.1080/003655299750025624]
17. de Silva DG, Mendis LN, Sheron N, Alexander GJ, Candy DC, Chart H, Rowe B. Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut 1993; 34: 194-198 [PMID: 8432472 DOI: 10.1136/gut.34.2.194]
18. Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004; 39: 1113-1118 [PMID: 15545170 DOI: 10.1080/00365520410003614]
19. Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3521-3529 [PMID: 10606314 DOI: 10.1111/j.1572-0241.1999.01641.x]
20. Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, Nakagawa K, Kayazawa M, Hirata I, Katsu K. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3513-3520 [PMID: 10606313 DOI: 10.1111/ j.1572-0241.1999.01640.x]
21. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853 [PMID: 12740341 DOI: 10.1136/gut.52.6.847]
22. Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol 2006; 359: 961-972 [PMID: 16690079 DOI: 10.1016/j.jmb.2006.04.009]
23. Pröpper C, Huang X, Roth J, Sorg C, Nacken W. Analysis of the MRP8-MRP14 protein-protein interaction by the two-hybrid system suggests a prominent role of the C-terminal domain of S100 proteins in dimer formation. J Biol Chem 1999; 274: 183-188 [PMID: 9867828 DOI: 10.1074/jbc.274.1.183]
24. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798 [PMID: 1411288 DOI: 10.3109/00365529209011186]
25. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-39 [PMID: 17924558 DOI: 10.1002/ibd.20275]
26. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-513 [PMID: 10986210 DOI: 10.1136/gut.47.4.506]
27. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369 [PMID: 20634346 DOI: 10.1136/bmj.c3369]
28. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460 [PMID: 12145798 DOI: 10.1053/gast.2002.34755]
29. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642-647 [PMID: 14563186 DOI: 10.1016/ S1590-8658(03)00381-5]
30. D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429-437 [PMID: 16838143 DOI: 10.1007/s00384-006-0159-9]
31. Canani RB, de Horatio LT, Terrin G, Romano MT, Miele E, Staiano A, Rapacciuolo L, Polito G, Bisesti V, Manguso F, Vallone G, Sodano A, Troncone R. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006; 42: 9-15 [PMID: 16385247 DOI: 10.1097/01.mpg.0000187818.76954.9a]
32. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003; 49: 861-867 [PMID: 12765980 DOI: 10.1373/49.6.861]
33. Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005; 40: 450-455 [PMID: 15795593 DOI: 10.1097/01.MPG.0000154657.08994.94]
34. Bini EJ, Lascarides CE, Micale PL, Weinshel EH. Mucosal abnormalities of the colon in patients with portal hypertension: an endoscopic study. Gastrointest Endosc 2000; 52: 511-516 [PMID: 11023569 DOI: 10.1067/mge.2000.108478]
35. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706-1713 [PMID: 17675327 DOI: 10.1136/gut.2006.113431]
36. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-169 [PMID: 17916108 DOI: 10.1111/ j.1572-0241.2007.01556.x]
37. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-410 [PMID: 19174795 DOI: 10.1038/ajg.2008.86]
38. Schröder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Ther 2007; 26: 1035-1042 [PMID: 17877510 DOI: 10.1111/j.1365-2036.2007.03457.x]
39. Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005; 51: 117-126 [PMID: 15819166]
40. Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 841-845 [PMID: 12172403 DOI: 10.1097/00042737-200208000-00005]
41. Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008; 46: 1275-1280 [PMID: 18597588 DOI: 10.1515/CCLM.2008.246]
42. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008; 14: 359-366 [PMID: 18050298 DOI: 10.1002/ibd.20336]
43. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-2224 [PMID: 22344983 DOI: 10.1002/ibd.22917]
44. Jelsness-Jørgensen LP, Bernklev T, Moum B. Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission. Gastroenterol Res Pract 2013; 2013: 620707 [PMID: 23476638 DOI: 10.1155/2013/620707]
45. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010; 105: 1788, 1789-1794; quiz 1795 [PMID: 20389294 DOI: 10.1038/ajg.2010.156]
46. Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013; 38: 44-51 [PMID: 23668698 DOI: 10.1111/apt.12335]
47. Sydora MJ, Sydora BC, Fedorak RN. Validation of a pointof-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis 2012; 6: 207-214 [PMID: 22325175 DOI: 10.1016/j.crohns.2011.08.008]
48. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013; 50: 53-61 [PMID: 23129721 DOI: 10.1258/acb.2012.011272]
49. Furman DL, Cash BD. The role of diagnostic testing in irritable bowel syndrome. Gastroenterol Clin North Am 2011; 40: 105-119 [PMID: 21333903 DOI: 10.1016/j.gtc.2010.12.001]
50. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos C, Sorg C, Roth J. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999; 274: 25291-25296 [PMID: 10464253 DOI: 10.1074/jbc.274.36.25291]
51. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901 [PMID: 10399917 DOI: 10.1016/ S0092-8674(00)80801-6]
52. Foell D, Wittkowski H, Kessel C, Lüken A, Weinhage T, Varga G, Vogl T, Wirth T, Viemann D, Björk P, van Zoelen MA, Gohar F, Srikrishna G, Kraft M, Roth J. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4. Am J Respir Crit Care Med 2013; 187: 1324-1334 [PMID: 23611140 DOI: 10.1164/rccm.201209-1602OC]
53. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135 [PMID: 12070776 DOI: 10.1038/ sj.gene.6363861]
54. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-1389 [PMID: 12832707 DOI: 10.1093/rheumatology/keg385]
55. Foell D, Seeliger S, Vogl T, Koch HG, Maschek H, Harms E, Sorg C, Roth J. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613-617 [PMID: 12832680]
56. Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 2008; 216: 183-192 [PMID: 18729068 DOI: 10.1002/path.2394]
57. Däbritz J, Langhorst J, Lügering A, Heidemann J, Mohr M, Wittkowski H, Krummenerl T, Foell D. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis 2013; 19: 1130-1138 [PMID: 23377171 DOI: 10.1097/MIB.0b013e318280b1cd]
58. Däbritz J, Jenke A, Wirth S, Foell D. Fecal phagocytespecific S100A12 for diagnosing necrotizing enterocolitis. J Pediatr 2012; 161: 1059-1064 [PMID: 22796048 DOI: 10.1016/ j.jpeds.2012.06.003]
59. Däbritz J, Foell D, Wirth S, Jenke A. Fecal S100A12: identifying intestinal distress in very-low-birth-weight infants. J Pediatr Gastroenterol Nutr 2013; 57: 204-210 [PMID: 23549327 DOI: 10.1097/MPG.0b013e3182946eb2]
60. Sipponen T, Haapamäki J, Savilahti E, Alfthan H, Hämäläinen E, Rautiainen H, Koskenpato J, Nuutinen H, Färkkilä M. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47: 778-784 [PMID: 22519419 DOI: 10.3109/00365521.2012.677953]
61. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207-1212 [PMID: 20801771 DOI: 10.1136/gut.2010.211755]
62. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis 2006; 12: 566-572 [PMID: 16804393 DOI: 10.1097/01.ibd.0000227626.72271.91]
63. Karl J, Wild N, Tacke M, Andres H, Garczarek U, Rollinger W, Zolg W. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol 2008; 6: 1122-1128 [PMID: 18928937 DOI: 10.1016/j.cgh.2008.04.021]
64. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999; 37: 281-286 [PMID: 10353473 DOI: 10.1515/CCLM.1999.049]
65. Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol 1994; 357: 133-141 [PMID: 7762425]
66. Angriman I, Scarpa M, D'Incà R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007; 381: 63-68 [PMID: 17368600 DOI: 10.1016/ j.cca.2007.02.025]
67. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima AA, Cooper WH, Lee AG. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992; 30: 1238-1242 [PMID: 1583125]
68. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309-1314 [PMID: 12818275 DOI: 10.1111/j.1572-0241.2003.07458.x]
69. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1746-1754 [PMID: 19363798 DOI: 10.1002/ibd.20920]
70. Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 414-422 [PMID: 17414136 DOI: 10.1097/ MPG.0b013e3180308d8e]
71. Sidhu R, Wilson P, Wright A, Yau CW, D'Cruz FA, Foye L, Morley S, Lobo AJ, McAlindon ME, Sanders DS. Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther 2010; 31: 1365-1370 [PMID: 20331581 DOI: 10.1111/j.1365-2036.2010.04306.x]
72. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 252-267 [PMID: 7672721]
73. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-366 [PMID: 10446103 DOI: 10.1136/gut.45.3.362]
74. Meling TR, Aabakken L, Røseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996; 31: 339-344 [PMID: 8726300 DOI: 10.3109/00365529609006407]
75. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 524-534 [PMID: 16775498 DOI: 10.1097/00054725-200606000-00013]
76. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008; 51: 1283-1291 [PMID: 18543035 DOI: 10.1007/ s10350-008-9310-8]
77. Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein. Protein Sci 2010; 19: 2031-2044 [PMID: 20857498 DOI: 10.1002/pro.505]
78. Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann Surg Oncol 2007; 14: 2714-2720 [PMID: 17602267 DOI: 10.1245/s10434-007-9481-x]
79. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984 [PMID: 15266315 DOI: 10.1038/ sj.bjc.6602033]
80. Czub E, Herzig KH, Szaflarska-Popawska A, Kiehne K, Socha P, Woś H, Kamińska B, Błaszczyński M, Cichy W, Bała G, Brodzicki J, Grzybowska-Chlebowczyk U, Walkowiak J. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 1147-1150 [PMID: 17852864 DOI: 10.1080/00365520701320513]
81. Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis 2007; 13: 1374-1378 [PMID: 17577247 DOI: 10.1002/ ibd.20214]
82. Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders. Inflamm Bowel Dis 2009; 15: 1630-1634 [PMID: 19462434 DOI: 10.1002/ibd.20946]
83. Langhorst J, Choi KE. The role of human defensins in gastrointestinal diseases. Expert Rev Clin Immunol 2011; 7: 779-787 [PMID: 22014019 DOI: 10.1586/eci.11.62]
84. Langhorst J, Wieder A, Michalsen A, Musial F, Dobos GJ, Rueffer A. Activated innate immune system in irritable bowel syndrome? Gut 2007; 56: 1325-1326 [PMID: 17429012 DOI: 10.1136/gut.2007.125005]
85. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol 2011; 26: 1493-1499 [PMID: 21777275 DOI: 10.1111/j.1440-1746.2011.06846.x]
86. Annaházi A, Molnár T, Farkas K, Rosztóczy A, Izbéki F, Gecse K, Inczefi O, Nagy F, Földesi I, Szu{double acute}cs M, Dabek M, Ferrier L, Theodorou V, Bueno L, Wittmann T, Róka R. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis 2013; 19: 316-320 [PMID: 22550024 DOI: 10.1002/ibd.22996]
87. Ohman L, Stridsberg M, Isaksson S, Jerlstad P, Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol 2012; 107: 440-447 [PMID: 22233694 DOI: 10.1038/ajg.2011.458]
88. Camilleri M. Editorial: fecal granins in IBS: cause or indicator of intestinal or colonic irritation? Am J Gastroenterol 2012; 107: 448-450 [PMID: 22388024 DOI: 10.1038/ajg.2011.465]
89. Cremonini F, Cheng V, Lembo A. Diagnosing irritable bowel syndrome: no more million dollar work-up? Clin Gastroenterol Hepatol 2013; 11: 963-964 [PMID: 23644390 DOI: 10.1016/j.cgh.2013.04.030]
90. Begtrup LM, Engsbro AL, Kjeldsen J, Larsen PV, Schaffalitzky de Muckadell O, Bytzer P, Jarbøl DE. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 956-62. e1 [PMID: 23357491 DOI: 10.1016/ j.cgh.2012.12.038]
91. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004; 20: 615-621 [PMID: 15352909 DOI: 10.1111/ j.1365-2036.2004.02128.x]
92. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007; 42: 1440-1444 [PMID: 17852860 DOI: 10.1080/00365520701427094]